Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2024-05-03 Capital/Financing Update
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and includes a formal amendment (정정신고) to the original filing. It details specific financial terms such as interest rates, conversion price adjustments, put/call options, and collateral information. This type of regulatory filing for capital structure changes falls under the 'Capital/Financing Update' category.
2024-05-03 Korean
주주총회소집결의 (임시주주총회)
AGM Information Classification · 1% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company Clinomics, dated May 3, 2024. It outlines the date, time, location, and agenda items for the upcoming meeting. This type of document, which serves as a formal notification to shareholders regarding a meeting, falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to prepare for the meeting.
2024-05-03 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement from Clinomics regarding the setting of a record date for an upcoming Extraordinary General Meeting of shareholders. It does not contain the full proxy materials or the meeting results, but rather serves as a formal notice of a corporate action (setting a record date). Given the nature of the announcement and its brevity, it falls under the category of general regulatory filings.
2024-05-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. This type of filing is specifically used to report changes in significant share ownership (crossing thresholds) by major shareholders and related parties. In the provided taxonomy, this corresponds to the 'Major Shareholding Notification' category.
2024-05-02 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision on a paid-in capital increase (유상증자결정). It details the amendment of terms for a third-party allocation capital increase, including changes to the number of shares and the purpose of funds. This falls under the category of announcements regarding new share issues or capital changes.
2024-04-24 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from Clinomics regarding the 'Results of Securities Issuance' (증권 발행결과) specifically for a third-party paid-in capital increase (제3자배정 유상증자). It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-04-24 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.